BSE filing, NSE: VENUSREM. Summary written from the filing by ALFA Finder's alert engine.
Venus Remedies Ltd: key numbers
- Share price
- ₹1,303.60
- Market cap
- ₹1,743 Cr
- Revenue (annual)
- ₹769.6 Cr
- Net profit (annual)
- ₹102.8 Cr
- P/E (TTM)
- 14.3×Sector 46.1×
- Promoter holding
- 41.76%+0.00% QoQ
- FII holding
- 3.14%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Venus Remedies Ltd
All →Venus Remedies Q2 FY27 Results: Net Profit ₹25.6 Cr, Up 27.4% YoY
Venus Remedies Ltd reported revenue from operations of ₹218.8 Cr (+13.5% YoY) and net profit of ₹25.6 Cr (+27.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹25.6 Cr · +27.4% YoY
Venus Remedies Regulatory Approval
Venus Remedies Limited secured five marketing authorizations for drugs including Vancomycin and Meropenem across Kazakhstan, Peru, Kuwait, and Argentina. These regulatory approvals expand its global pharmaceutical portfolio.
Venus Remedies Board Meeting Date
Venus Remedies will hold a board meeting on 26th October 2026 to consider and approve its unaudited standalone and consolidated financial results for the September quarter.
Venus Remedies Other Announcement
Venus Remedies Limited has announced a change in its Corporate Identification Number (CIN) following the alteration of its Memorandum of Association.
Venus Remedies Other Announcement
Venus Remedies Limited has informed the exchanges about its social media posts regarding a special window for the re-lodgement of physical share transfer requests.
Venus Remedies Management Change
Venus Remedies Ltd announced the appointment and re-appointment of several Directors, including Executive and Independent Directors, following approval at its 37th Annual General Meeting.
Other other announcement announcements
All →Infronics Systems Other Announcement
Infronics Systems appointed R & A Associates as Secretarial Auditor for FY 2026-27. This is a routine statutory appointment with no financial impact.
- Execution
- FY 2026-27
Onix Solar Energy Other Announcement
Onix Solar Energy's monitoring agency reports its rights issue proceeds are fully utilised. The report covers the quarter ended 30 September 2026.
Steamhouse India Other Announcement
Steamhouse India's Reg 32 statement confirms no deviation in IPO fund utilisation from prospectus objects for the quarter ended September 30, 2026. It also discloses a rectified issue-expense figure reallocating Rs 53.5 million to general corporate purposes.
Pine Labs Other Announcement
Pine Labs Limited filed CARE Ratings' Monitoring Agency Report for the quarter ended September 30, 2026, on its IPO proceeds. The report shows no deviation from objects and no major deviations.
Sihora Industries Other Announcement
Sihora Industries reported IPO proceeds utilisation of Rs.983.87 lakh of Rs.1,056 lakh raised, to September 2026. Shareholders approved the object deviation on 17 August 2026.
Titan Company Other Announcement
Titan's employee stock option trust transferred 19,385 shares worth Rs.8.40 Crore to eligible employees after PSU exercise. The off-market transfer was disclosed under PIT Reg 7(2).
- Value
- ₹8.40 Cr